immunization Archives - Amazing Health Advances

Poll: Almost Half of U.S. Respondents Demand Reevaluation of CDC Vaccine Schedule

The AHA! Team — Wed, 13 Aug 2025 05:33:15 +0000

Ramon Tomey via Natural News – In a striking shift, nearly half of U.S. respondents in an opinion poll now support reexamining the childhood vaccination schedule recommended by the Centers for Disease Control and Prevention (CDC). A poll by Children’s Health Defense reveals 49.4 percent of respondents favor reviewing the CDC’s childhood vaccination schedule, while only 29.6 percent oppose changes. Support rises to nearly 60 percent among parents of young children. While 43 percent still back school vaccine requirements, 39 percent argue public education access should not depend on vaccination status. New CDC appointees, including Martin Kulldorff, are scrutinizing vaccine safety, including cumulative effects of ingredients. Critics accuse the panel of promoting “anti-vaccine” views. Nearly half (48 percent) support legal recourse for vaccine-related harm, challenging the 1986 law shielding manufacturers from liability. The CDC’s review of thimerosal in flu shots revisits past autism concerns. The poll reflects eroded trust in vaccine mandates, signaling a shift away from unquestioned acceptance. In a striking shift, nearly half of U.S. respondents in an opinion poll now support reexamining the childhood vaccination schedule recommended by the Centers for Disease Control and Prevention (CDC). The survey, conducted by John Zogby Strategies and commissioned by Children’s Health Defense (CHD), polled 1,006 respondents from June 24 to 25. It found that 49.4 percent – 23.7 percent strongly support, 25.7 percent somehow support – are in favor of a reevaluation of the CDC’s vaccine schedule. In contrast, only 29.6 percent of respondents – 15.1 percent strongly oppose, 14.5 percent somewhat oppose – prefer to keep the vaccination schedule as is. The poll’s results also revealed that support for reviewing the vaccine schedule spikes to almost 60 percent among parents of young children – a demographic directly impacted by the recommendations. Under the current schedule, children must be injected with 70 doses of 15 vaccines by age 18. Meanwhile, 43 percent of respondents still endorse school vaccine mandates. Nevertheless, 39 percent of respondents argue public education access should remain unconditional instead of being contingent on compliance with vaccine mandates. (Related: MASS EXODUS from public schools anticipated after CDC advisory panel unanimously votes to add deadly Covid-19 “vaccines” to childhood immunization schedule.) People want vaccine injury accountability The opinion poll’s results come amid escalating scrutiny of federal vaccine policies, particularly after Health Secretary Robert F. Kennedy Jr. overhauled the CDC’s Advisory Committee on Immunization Practices (ACIP) with appointees who criticize mainstream vaccine guidance. Central to the controversy is a newly formed CDC work group tasked with studying the cumulative effects of childhood vaccines. “It is important to evaluate interaction effects between different vaccines, cumulative amounts of vaccine ingredients, and relative timing,” said new ACIP Chairman Martin Kulldorff during the panel’s June 25 meeting. His remarks echoed a 2013 National Academy of Medicine report urging deeper research into vaccine safety, a call left unheeded for over a decade. Critics, including mainstream medical groups, accuse the panel of veering toward anti-vaccine ideology. The American Academy of Pediatrics blasted Kulldorff’s suggestion to delay hepatitis B vaccinations as “unscientific” and “dangerous.” Typically given at birth, the new ACIP chairman said the injection can be delayed “unless the mother is hepatitis B positive.” Yet CHD CEO Mary Holland argues the poll reflects a public revolt against institutional dogma. “The constant fearmongering and shaming tactics … are not only ineffective, but backfiring,” she said. “This data clearly shows that the mainstream media, medical establishment and many politicians fail to hear the serious concerns of half of Americans on these vital issues.” Equally contentious is the 1986 National Childhood Vaccine Injury Act, which shields manufacturers from liability. Nearly half of respondents – 48 percent – now support legal recourse for vaccine injuries. In contrast, just 34 percent defend the status quo. This debate started in the 1990s, when mercury-based thimerosal first ignited autism concerns. Kennedy has long cited studies linking vaccines to neurological harm, though federal agencies and major medical journals reject those claims. Thimerosal was later removed from most childhood vaccines in 2001. The new ACIP’s review of thimerosal-preserved flu shots reignites that clash. Whether the CDC’s review yields policy changes or further polarization, one truth is clear. The era of unquestioned vaccine mandates is over. Sources include: ChildrensHealthDefense.org 1 ChildrensHealthDefense.org 2 [PDF] NBCNews.com Brighteon.com To read the original article, click here

The post Poll: Almost Half of U.S. Respondents Demand Reevaluation of CDC Vaccine Schedule appeared first on Amazing Health Advances.

Pfizer to Seek Approval for COVID Vaccine ‘Within Days’

AHA Publisher — Fri, 20 Nov 2020 08:00:11 +0000

Tré Goins-Phillips, Faithwire via CBN News – The pharmaceutical giant Pfizer announced Wednesday it will seek regulatory approval for its COVID-19 vaccine “within days.” Working in partnership with the German group BioNTech, Pfizer has completed its Phase 3 trial and has deemed the vaccination 95% effective at preventing COVID-19 infections, NBC News reported, up from 90% last week. Former Food and Drug Administration Commissioner Dr. Scott Gottlieb, who serves as an independent member on Pfizer’s board of directors, described the development as a “game change,” adding the successes in vaccine development “could effectively end the U.S. epidemic next year.” To date, there have been no serious side effects for the 41,135 adults who received two doses of the Pfizer vaccine. The most common reaction among trial participants were that 3.7% experienced fatigue and 2% had headaches. Only eight of those who received the Pfizer vaccination fell ill to COVID-19. By comparison, 162 of those who received the placebo became sick. “The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,” Pfizer Chairman and CEO Dr. Albert Bourla said in a statement. “With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world.” The companies — Pfizer and BioNTech — announced their joint plan to seek emergency use authorization from the FDA “within days.” The groups are also sharing their findings with regulators in Europe. Pfizer’s data shows the vaccination 95% effective against future infections beginning 28 days after the first two doses. The immunization’s effectiveness was found to be consistent across all age and race demographics. Furthermore, its side effects wore off “shortly after vaccination,” and among older adults, they tended to be “fewer and milder.” News of Pfizer’s rapidly evolving vaccine comes just a couple days after the biotech company Moderna announced its COVID-19 vaccine is 94.5% effective against infection. Moderna President Dr. Stephen Hogue described the development as a “really important milestone,” adding he’s reassured by the fact that Pfizer has released similar findings. “That should give us all hope that actually a vaccine is going to be able to stop this pandemic and hopefully get us back to our lives,” he added. Both the Moderna and Pfizer vaccines were developed using messenger RNA, tiny pieces of genetic code injected into the body to trick the immune system into producing a response to fend off COVID-19 without actually having to inject actual bits of the virus. Anything Else? This week, CNN’s Jake Tapper and Dr. Sanjay Gupta praised President Donald Trump’s administration for its work to facilitate the production of a COVID-19 vaccine at breakneck speed. “It’s important that people working so hard — Monsef Slaoui and the others — get credit for this, and President Trump was the one who OK’d it,” Tapper said. Gupta agreed, adding, “No doubt. The pace of medical innovation has been forever changed. I mean, three months, Jan. 11 is when they got the sequence of this virus. By March 16, two months later, shots were going into arms as part of these clinical trials. I couldn’t believe it when I saw that pace. It typically takes, you know, years to really get these vaccines approved. It’ll be done within a year. That is worth celebrating, and now we have some early data to be very optimistic about.” “So all of the scientists, everyone behind this, all the way up to President Trump and Vice President Pence, congratulations on this great accomplishment,” said Tapper. Trump, for his part, thanked Tapper and Gupta for their comments. To read the original article click here. For more articles from CBN News click here.

The post Pfizer to Seek Approval for COVID Vaccine ‘Within Days’ appeared first on Amazing Health Advances.

Israel to Begin Clinical Trials of Covid-19 Vaccine

AHA Publisher — Tue, 27 Oct 2020 07:00:19 +0000

Abigail Klein Leichman via Israel21c – The governmental Israel Institute for Biological Research (IIBR) has approval from the Ministry of Health and the Helsinki Committee to begin testing its vaccine, BriLife, against the SARS-CoV-2 coronavirus on November 1. The IIBR has prepared 25,000 doses of BriLife and has recruited the first volunteers in an 80-person clinical trial, 40 at Hadassah University Medical Center in Jerusalem and 40 at Sheba Medical Center in Ramat Gan. Each volunteer, aged 18 to 55, will receive an injection (vaccine or placebo). After a few hours of supervision he/she will be discharged and monitored for three weeks for any possible side effects and for the development of antibodies to the virus in response to the vaccine. The second phase will include extensive safety tests on 960 healthy volunteers, to begin in December in several medical centers across Israel. In this phase, scientists aim to complete vaccine safety precautions, determine effective dosage, and further determine the vaccine’s effectiveness. The third and final phase is a large-scale trial to test the effectiveness of BriLife, with the participation of up to 30,000 volunteers. Subject to the success of the first two phases, this phase is scheduled to begin in April or May. If it is successful, the vaccine may be approved for mass use. On June 21, ISRAEL21c reported that a single dose of the IIBR’s recombinant VSV-∆G-spike vaccine “results in rapid and potent induction of neutralizing antibodies against SARS-CoV-2” in Syrian golden hamsters in a successful preclinical trial. It was also tested successfully in mice, rabbits and pigs, paving the way to human trials. “Our final goal is 15 million doses for the residents of the State of Israel and for our close neighbors,” said Prof. Shmuel Shapira, director of the IIBR. The research institute in Ness Ziona, which is part of the Ministry of Defense, has been directing all its efforts in the past few months toward novel coronavirus research. In collaboration with several partners, the IIBR also is developing an antibody-based Covid-19 treatment and a new method to detect the virus through breath analysis. Shapira said the name BriLife puts together the Hebrew word for health, briut, with “il” for Israel and “life” — which speaks to the importance of the vaccine. To read the original article click here. For more articles from Israel21c click here.

The post Israel to Begin Clinical Trials of Covid-19 Vaccine appeared first on Amazing Health Advances.